Filing Analysis
Faeth Therapeutics entered into an At-The-Market (ATM) offering agreement with TD Securities to sell up to $150 million in common stock. Additionally, the company reported the automatic conversion of Series B Preferred Stock into approximately 24.4 million shares of common stock.
🚩 Red Flags
- Extreme dilution potential: The $150M ATM offering is massive relative to the current outstanding share count of ~25.8 million shares.
- Multiple 8-K items (1.01 and 8.01) reported in a single filing.
- Significant increase in share count due to the automatic conversion of Preferred Stock just prior to the ATM announcement.
📋 Key Facts
- Entered into a Sales Agreement on June 18, 2026, with TD Securities (USA) LLC.
- The ATM offering allows for the sale of common stock with an aggregate offering price of up to $150,000,000.
- The Agent (TD Securities) will receive a commission of up to 3.0% of gross sales.
- On June 15, 2026, 24,435.594 shares of Series B Non-Voting Convertible Preferred Stock converted into 24,435,594 shares of Common Stock.
- Total Common Stock outstanding as of June 15, 2026, is 25,778,754 shares.
The company has undergone a comprehensive corporate restructuring, including a name change to Faeth Therapeutics, Inc., a complete overhaul of the executive leadership team, and a reorganization of the Board of Directors. Additionally, the company terminated a $50 million equity sales agreement with Jefferies LLC without having utilized any of the funds.
🚩 Red Flags
- Simultaneous execution of multiple high-impact changes: name change, CEO/CFO replacement, and Board turnover.
- Termination of a $50M funding facility (Jefferies) without ever utilizing it, suggesting a shift in capital strategy or failure of the previous financial plan.
📋 Key Facts
- Company name changed from Sensei Biotherapeutics, Inc. to Faeth Therapeutics, Inc. effective June 15, 2026.
- Anand Parikh appointed as President and CEO effective June 13, 2026, with a base salary of $680,000 and a 60% target bonus.
- Brian Stephenson appointed as CFO and Josiah Craver appointed as principal accounting officer effective June 13, 2026.
- Three directors (Christopher W. Gerry, Thomas Ricks, and Kristian Humer) resigned on June 12, 2026.
- Two new directors appointed: Stephen M. Hahn (former FDA Commissioner) and Saira Ramasastry (Life Sciences Advisory, LLC).
- Terminated a Prior Sales Agreement with Jefferies LLC (dated March 15, 2022) that allowed for up to $50 million in stock offerings; no shares were sold under this agreement.
- Board size reduced from six to five members, with Anand Parikh appointed as Board Chair.
Sensei Biotherapeutics held its 2026 Annual Meeting where stockholders approved a massive increase in authorized common stock and the conversion of Series B Preferred Stock, which will result in a change of control of the company.
🚩 Red Flags
- Extreme dilution: Increasing authorized shares from 12.5M to 300M is a massive expansion of the capital structure, typical of companies preparing for significant equity raises or facing severe capital constraints.
- Change of Control: The conversion of Series B Preferred Stock explicitly results in a change of control of the company.
- Significant opposition to equity plans: Proposal No. 5 (Equity Incentive Plan) and Proposal No. 6 (ESPP) saw substantial 'Against' votes (approx 266k and 262k respectively), indicating shareholder friction.
📋 Key Facts
- Authorized common stock increased from 12,500,000 to 300,000,000 shares (a 24x increase).
- Stockholders approved the conversion of Series B Non-Voting Convertible Preferred Stock, which will result in a change of control per Nasdaq Listing Rules 5635(a) and 5635(b).
- Approved the 2026 Equity Incentive Plan with an initial reserve of 2,671,981 shares plus potential carry-overs from the 2021 plan.
- Approved the 2026 Employee Stock Purchase Plan (ESPP) with an initial reserve of 267,198 shares.
- Ratified Deloitte & Touche LLP as the independent auditor for fiscal year 2026.
- Elected Bob Holmen and Kristian Humer to the Board of Directors.
Sensei Biotherapeutics announced a delay in the planned board appointment of Dr. Karen Vousden due to personal reasons, with plans to reconsider her appointment in Q3 or Q4 2026. Additionally, the company plans to appoint Bob Holmen as chair of the Nominating and Corporate Governance Committee and set the board size to five directors, effective June 12, 2026, subject to stockholder approval.
🚩 Red Flags
- Last-minute delay in a planned board appointment right before the annual meeting.
📋 Key Facts
- Dr. Karen Vousden requested her appointment to the Board be delayed until later in 2026 due to personal reasons.
- The Board intends to consider appointing Dr. Vousden in the third or fourth quarter of 2026.
- Bob Holmen is planned to be appointed as chair of the Nominating and Corporate Governance Committee, effective June 12, 2026.
- The Board approved a Board size of five directors effective June 12, 2026.
- The changes are contingent on stockholder approval of the Required Company Stockholder Matters at the Annual Meeting on June 10, 2026.
Sensei Biotherapeutics, Inc. (SNSE) filed an 8-K disclosing unaudited pro forma financial information related to the proposed conversion of Series B Non-Voting Convertible Preferred Stock into common stock, ahead of its June 10, 2026 Annual Meeting. The conversion will result in issuance of shares representing more than 20% of outstanding common stock and will trigger a change of control under Nasdaq Listing Rules 5635(a) and 5635(b). Stockholder approval for the conversion is being sought at the Annual Meeting.
🚩 Red Flags
- Conversion of Series B Preferred Stock will exceed 20% dilution threshold, triggering Nasdaq Rule 5635(a) — significant dilution risk for existing common stockholders
- Change of control triggered under Nasdaq Rule 5635(b) — existing shareholders face major ownership/governance shift
- Pro forma financial information is unaudited and preliminary, with management cautioning actual financial condition may differ materially
- Office relocation from Boston, MA to Rockville, MD may signal operational restructuring or leadership changes
- Conversion economics and full dilution impact not fully quantified in the 8-K text itself — detail only in Exhibit 99.1
- Multiple Nasdaq listing rules triggered simultaneously (5635(a) and 5635(b)) indicates a highly material equity event
📋 Key Facts
- Annual Meeting scheduled for June 10, 2026 at 11:00 a.m. Eastern Daylight Time
- Stockholders will vote on issuance of common stock upon conversion of Series B Non-Voting Convertible Preferred Stock (par value $0.0001/share)
- Conversion will represent MORE than 20% of shares of common stock outstanding — triggering Nasdaq Rule 5635(a)
- Conversion will result in a CHANGE OF CONTROL of the Company — triggering Nasdaq Rule 5635(b)
- Pro forma financial information is based on Q1 2026 (quarter ended March 31, 2026) historical financials
- 10-Q for Q1 2026 was filed with the SEC on May 15, 2026
- Definitive Proxy Statement filed with the SEC on April 27, 2026
- Company relocated principal offices from 451 D Street, Suite 710, Boston, MA to 1405 Research Blvd, Suite 125, Rockville, MD 20850
- Filing signed by Christopher W. Gerry, President and General Counsel
- Company is classified as an emerging growth company
Sensei Biotherapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- The filing was made on May 15, 2026, reporting on the quarter ended March 31, 2026.
- The company utilized Item 2.02 (Results of Operations and Financial Condition) to furnish the information.
- Exhibit 99.1 contains the full press release regarding the financial results.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Sensei Biotherapeutics announced a comprehensive board and management overhaul contingent on shareholder approval of a massive recapitalization plan. The plan involves increasing authorized common shares from 12.5 million to 300 million and a change of control through the conversion of Series B Preferred Stock.
🚩 Red Flags
- Massive potential dilution with authorized shares increasing from 12.5M to 300M.
- Explicit 'change of control' triggered by preferred stock conversion.
- Simultaneous turnover of the Board, CEO, and CFO positions.
- Adoption of a new executive severance plan immediately preceding a change of control.
📋 Key Facts
- Three directors (Christopher W. Gerry, Thomas Ricks, and Kristian Humer) tendered conditional resignations effective June 2026.
- The company plans to increase authorized common shares by 2,300%, from 12,500,000 to 300,000,000.
- A change of control is expected following the conversion of Series B Non-Voting Convertible Preferred Stock into common stock representing >20% of outstanding shares.
- Anand Parikh (current COO) is slated to become CEO, and Brian Stephenson is slated to become CFO.
- Former FDA Commissioner Stephen M. Hahn is among the three new conditional board appointments.
- A new Severance and Change in Control Plan was adopted on April 10, 2026, providing up to 18 months of base salary for the CEO upon termination.
This is an 8-K/A (Amendment No. 1) filed to provide supplemental financial data regarding the previously reported acquisition of Faeth Holdings Therapeutics, Inc. and its subsidiary, Faeth Therapeutics, LLC. The amendment specifically adds audited financial statements for the acquired entity and unaudited pro forma combined financial information.
📋 Key Facts
- The filing is an amendment to a report originally filed on February 18, 2026.
- The transaction involved the acquisition of Faeth Holdings Therapeutics, Inc. and Faeth Therapeutics, LLC.
- Audited financial statements for Faeth Subsidiary for the years ended December 31, 2024 and 2025 were provided (Exhibit 99.3).
- Unaudited pro forma condensed combined financial information as of December 31, 2025 was provided (Exhibit 99.4).
- The acquisition involved a Securities Purchase Agreement and the issuance of Series B Non-Voting Convertible Preferred Stock.
Sensei Biotherapeutics announced its full-year 2025 financial results on March 30, 2026. The filing also indicates a relocation of the company's principal executive offices from Boston, MA to Rockville, MD.
📋 Key Facts
- Released full-year financial results for the period ended December 31, 2025, on March 30, 2026.
- Principal executive office address changed from 451 D Street, Boston, MA to 1405 Research Blvd, Rockville, MD.
- The financial information was furnished under Item 2.02 and is not deemed 'filed' for regulatory purposes.